DelveInsight’s Trigeminal Neuralgia Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Trigeminal Neuralgia (TN), historical and forecasted epidemiology as well as the Trigeminal Neuralgia (TN) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Trigeminal Neuralgia (TN) market report provides current treatment practices, emerging drugs, Trigeminal Neuralgia (TN) market share of the individual therapies, and current and forecasted Trigeminal Neuralgia (TN) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Trigeminal Neuralgia (TN) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Trigeminal Neuralgia (TN) market.
Trigeminal Neuralgia: An Overview
Trigeminal Neuralgia (TN), also known as tic douloureux, is a chronic pain condition that affects the trigeminal or fifth cranial nerve, one of the most widely distributed nerves in the head. It is a form of neuropathic pain (pain associated with nerve injury or nerve lesion) and is categorized into two types: primary (idiopathic) and secondary.
Download a sample copy of the market report- https://www.delveinsight.com/sample-request/trigeminal-neuralgia-tn-market
Key highlights of the Trigeminal Neuralgia Market Report
- As per the National Organization for Rare Disorders (NORD), trigeminal neuralgia affects females slightly more often than males. Although the exact incidence is unknown, approximately 10,000–15,000 new cases occur each year in the United States.
- A study conducted by Obermann M (2010) in Germany indicated that the incidence of trigeminal neuralgia is 4.3 per 100,000 persons per year, with a slightly higher incidence for women (5.9 per 100,000) as compared to men (3.4 per 100,000). There is a lack of certainty regarding the etiology and pathophysiology.
- A study conducted by Manzoni et al. (2005) in Italy stated that trigeminal neuralgia has an incidence ranging from about 4–5 per 100,000 per year up to 20 per 100,000 per year after age 60. The female-to-male ratio is about 3:2.
Trigeminal Neuralgia Market
the trigeminal Neuralgia market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of the Trigeminal Neuralgia Market in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Trigeminal Neuralgia Market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Trigeminal Neuralgia Market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Trigeminal Neuralgia Treatment Market
The first line of treatment for patients with trigeminal neuralgia is always medication. The drugs most commonly used for treating trigeminal neuralgia are medications that were originally developed for the treatment of epilepsy. However, this class of medications has been found to be quite effective in treating nerve pain, including TN, when taken on an on-going basis. The anti-convulsant most commonly prescribed for TN is carbamazepine (Tegretol), which can provide at least partial pain relief for up to 80% to 90% of patients. Other anti-convulsants prescribed frequently for TN include phenytoin (Dilantin), gabapentin (Neurontin), lamotrigine (Lamictal), oxcarbazepine (Trileptal), and topiramate (Topamax). The muscle relaxant baclofen (Lioresal) can also be prescribed, alone or in combination with other drugs.
Trigeminal Neuralgia Market Insights
To counter unmet market needs and provide better treatment choices for TN, several market players are working robustly either on single-agent novel molecules or on combination and dose modification of standard therapies. Several therapies are expected to be launched in the study period, likely to drive market growth during the study period. A few major market players in Trigeminal Neuralgia market include Noema Pharma AG, Biohaven Pharmaceuticals, among others.
Trigeminal Neuralgia Emerging Therapies
- Basimglurant (Noema Pharma AG)
- Rimegepant (Biohaven Pharmaceuticals)
Trigeminal Neuralgia Market Forecast
Anticonvulsant drugs, muscle relaxants, and neuroleptic agents are the preferred medical treatment for trigeminal neuralgia. Large placebo-controlled clinical trials are scarce, and no specific established substance has been developed for the treatment of trigeminal neuralgia.
Trigeminal Neuralgia Market Dynamics
The dynamics of Trigeminal Neuralgia (TN) market is expected to change due to the improvement in the diagnosis, incremental healthcare expenditure across the world and expected launch of emerging therapies during the forecast period of 2019─2032. Companies all over the globe are persistently working toward the development of new treatment therapies, such as Noema Pharma AG, Biohaven Pharmaceuticals and others.
Trigeminal Neuralgia Companies and Therapies
- Rimegepant: Biohaven Pharmaceuticals
Request a sample copy of the market report- https://www.delveinsight.com/sample-request/trigeminal-neuralgia-tn-market
Table of Content
1. Key Insights
2. Executive Summary of Trigeminal Neuralgia (TN)
3. Competitive Intelligence Analysis for Trigeminal Neuralgia (TN)
4. Trigeminal Neuralgia (TN): Market Overview at a Glance
5. Trigeminal Neuralgia (TN): Disease Background and Overview
5.5. Diagnosis
6. Patient Journey
7. Trigeminal Neuralgia (TN) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Trigeminal Neuralgia (TN) Unmet Needs
10. Key Endpoints of Trigeminal Neuralgia (TN) Treatment
11. Trigeminal Neuralgia (TN) Marketed Products
12. Trigeminal Neuralgia (TN) Emerging Therapies
13. Trigeminal Neuralgia (TN): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Trigeminal Neuralgia (TN)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash
info@delveinsight.com
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/